Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Peter Voorhees, Meletios Dimopoulos, Yaël Cohen et al. Nov 03, 2025 pp. 372-372 10.1182/blood-2025-372

Abstract Introduction : Current standard of care for smoldering multiple myeloma (SMM), an asymptomatic precursor of mul...

First-in-class small molecule calmodulin pathway modulators attenuate excess p53 activity and correct erythropoietic defects in models of diamond-blackfan anemia (DBA)

Avik Choudhuri, Heather Corry, Brian Lucas et al. Nov 03, 2025 pp. 1441-1441 10.1182/blood-2025-1441

Abstract Diamond-Blackfan Anemia (DBA) is a rare congenital bone marrow failure disorder with patients manifesting macrocytic anemia in infa...

Novel microfluidic rheology assay for in vitro-differentiated red blood cells: Enhancing quality control and therapeutic evaluation in sickle cell disease gene therapies

Solomon Oshabaheebwa, Yuxuan Du, Christopher Wirth et al. Nov 03, 2025 pp. 6489-6489 10.1182/blood-2025-6489

Abstract Introduction Gene therapies for sickle cell disease (SCD) edit hematopoietic stem cells (HSCs) to generate healthy red blood cells...

RAG1/2 expression in follicular lymphoma marks candidate precursor cells of high-grade B cell lymphoma with MYC and BCL2 rearrangements

Stefano Casola, Silvia Lonardi, Piera Balzarini et al. Nov 03, 2025 pp. 3534-3534 10.1182/blood-2025-3534

Abstract High-grade B cell lymphoma with MYC and BCL2 rearrangements (HGBCL-DH-BCL2) represent an infrequent, life-threatening clinical enti...

Deep neutrophil phenotyping uncovers complement-mediated neutrophil dysregulation in sickle cell disease

William Briones, Seema Patel, Maya Maarouf et al. Nov 03, 2025 pp. 12-12 10.1182/blood-2025-12

Abstract Introduction Sickle cell disease (SCD) impacts millions globally. Acute chest syndrome (ACS) is the leading cau...

Deciphering the mechanistic role of mixed lineage leukemia partial tandem duplications (MLLPTD) in MDS and AML

Roberta Dollinger, Audrey Kopp, Mehar Un Nissa et al. Nov 03, 2025 pp. 3238-3238 10.1182/blood-2025-3238

Abstract The mixed lineage leukemia (MLL) methyltransferase gene is a member of the trithorax group family of factors and plays a significan...

Diffuse fractures in a neonate with homozygous UROS C73R congenital erythropoietic porphyria: An unreported phenotype

Ahsan Wahab, Aashika Janwadkar, Moujtaba Zahweh et al. Nov 03, 2025 pp. 4681-4681 10.1182/blood-2025-4681

Abstract Introduction: Congenital erythropoietic porphyria (CEP) is an ultra-rare autosomal recessive disorder, usually...

Refining diffuse large B-cell lymphoma subtyping using lymphly, an evidence-based classifier

Dmitrii Snitkin, Pavel Zemskiy, Andrey Suponin et al. Nov 03, 2025 pp. 2557-2557 10.1182/blood-2025-2557

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is clinically and genetically heterogeneous, with 20–40% of patients relapsing af...

Pregnancy outcomes in women conceiving after HSCT for childhood or adolescent leukemia

Paul Saultier, Loic Guillerault, Carine Domenech et al. Nov 03, 2025 pp. 1056-1056 10.1182/blood-2025-1056

Abstract Background: Myeloablative conditioning delivered before childhood or adolescent hematopoietic stem-cell transplantation (HSCT) redu...

The profile of clinical and laboratory features of Chinese vexas syndrome patients with hematological abnormalities: A single-center case series

Xiang Ren, Min Wang, Jiali Huo et al. Nov 03, 2025 pp. 6702-6702 10.1182/blood-2025-6702

Abstract VEXAS syndrome is a recently characterized hemato-inflammatory disorder caused by somatic mutations in the X-linked UBA1 gene in he...

Clonal hematopoiesis and lung adenocarcinoma pathogenesis

Peter Miller, Tiziana Parisi, Adam Sperling et al. Nov 03, 2025 pp. 4940-4940 10.1182/blood-2025-4940

Abstract Background and Objective: Clonal hematopoiesis (CH) arises from expansion of hematopoietic stem cells bearing somatic mutations, an...

Targeted capture sequencing identifies driver mutations and enables prognostic modeling in multiple myeloma

Yang Yang, Donghua He, Jingsong He et al. Nov 03, 2025 pp. 5778-5778 10.1182/blood-2025-5778

Abstract Introduction Multiple myeloma (MM) remains incurable with pronounced prognostic heterogeneity, driven by extensive genomic complexi...

Dermatologic adverse effects with elranatamab mimicking talquetamab

M Bakri Hammami, Sean Haney, Daniel DeAvila et al. Nov 03, 2025 pp. 2200-2200 10.1182/blood-2025-2200

Abstract Bispecific antibodies (BsAbs) have become an important therapeutic option for patients with relapsed/refractory multiple myeloma (R...

PSMD3 orchestrates metabolic reprogramming and immunogenic cell death in multiple myeloma

Teng Fang, Ting Du, Arghya Ray et al. Nov 03, 2025 pp. 3926-3926 10.1182/blood-2025-3926

Abstract Background and Rationale Multiple myeloma (MM) is a cancer of the plasma cells characterized by excessive production of immunoglobul...

Clinical features and outcomes of acquired versus baseline TP53 mutations in myeloid neoplasms: A single-center retrospective analysis

Jason Gilbert, Megan Othus, Suravi Raychaudhuri et al. Nov 03, 2025 pp. 7022-7022 10.1182/blood-2025-7022

Abstract Background: TP53 encodes a tumor suppressor protein that plays a critical role in regulating cell division and apoptosis. While mut...

CRISPR-Cas9 screen-driven identification of metabolic vulnerabilities reveals synthetic lethality via synergistic targeting of mitochondrial energy pathways and lactate export in oxphos-dependent T-ALL

Natalia Baran, Alessia Lodi, Shraddha Patel et al. Nov 03, 2025 pp. 1538-1538 10.1182/blood-2025-1538

Abstract T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive hematologic malignancy driven by uncontrolled proliferation of i...

Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)

Ricardo Parrondo, Ricardo de Menezes, Hanna Sledge et al. Nov 03, 2025 pp. 4585-4585 10.1182/blood-2025-4585

Abstract Background: The phase II and III GRIFFIN and PERSEUS studies evaluated DVRd vs. VRd in NDMM pts that were transplant eligible (TE)....

Interest, barriers, and motivators for pursuing hematology electives among fourth-year Caribbean medical students: A cross-sectional survey

Amruth Alluri, Jason Truong, Yashaswi Guntupalli Nov 03, 2025 pp. 4652-4652 10.1182/blood-2025-4652

Abstract Background: The evolving complexity of hematology necessitates early engagement of medical students to sustain a skilled and divers...

A comprehensive analysis of PCR for BCR::ABL1 and next-generation sequencing (NGS)-based measurable residual disease (MRD) with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Prevalence, association with transcript type, and clinical outcomes

Manuel Maroun, Hagop Kantarjian, Nitin Jain et al. Nov 03, 2025 pp. 551-551 10.1182/blood-2025-551

Abstract Background: NGS for IG/TCR rearrangements is a highly sensitive tool for detecting MRD in ALL. NGS MRD negativity with low-level de...

High dose iron infusions in pregnant women are effective, safe, and well-tolerated

Steven Fein, Dayne Alonso, Gloria Campos et al. Nov 03, 2025 pp. 2703-2703 10.1182/blood-2025-2703

Abstract Background: Iron infusions in pregnant women who have iron deficiency anemia (IDA) have been shown to be effective, safe, and well-...

Pola-R-CHP in previously untreated diffuse large B-cell lymphoma: Real-world data in Russia

Gayane Tumyan, Anastasia Semenova, Yulia Ermakova et al. Nov 03, 2025 pp. 1913-1913 10.1182/blood-2025-1913

Abstract Introduction: Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) was approved...

A decisional intervention for older patients with Acute Myeloid Leukemia and their oncologist: A pilot randomized controlled trial (RCT)

Kah Poh (Melissa) Loh, Soroush Mortaz-Hedjri, Rachel Blumberg et al. Nov 03, 2025 pp. 1081-1081 10.1182/blood-2025-1081

Abstract Introduction: Treatment shared decision-making (SDM) is challenging for older adults with newly diagnosed acute myeloid leukemia (A...

Chidamide reprograms AML-associated macrophages via HDAC3 inhibition to boost CD8+ T cell immunity

Zhili Tan, Yujie Zhang, Ziyi liang et al. Nov 03, 2025 pp. 1494-1494 10.1182/blood-2025-1494

Abstract Introduction: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by frequent relapse and treatment...

Digital cognitive behavioral therapy vs. education intervention in population with sickle cell disease experiencing pain: A systematic review

Carla Miret Durazo, Joceline Almeida Hidalgo, Manju Ramakrishnan et al. Nov 03, 2025 pp. 6511-6511 10.1182/blood-2025-6511

Abstract Introduction: Chronic pain in sickle cell disease (SCD) patients impairs daily functioning and quality of life, despite advances in...

Inhibition of platelet kinase signaling and scaffolding activities with small molecule proteolysis-targeting chimeras (PROTACs)

Eliana Choi, Yiheng Zhang, Raquel Mote et al. Nov 03, 2025 pp. 3020-3020 10.1182/blood-2025-3020

Abstract Tyrosine kinase inhibitors (TKIs) play an expanding role in treating cancers and other diseases, including thromboinflammatory and...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page